MTN-035, or DESIRE (Developing and Evaluating Short-acting Innovations for Rectal Use), is an open label crossover study to systematically examine multiple placebo methods for delivering drugs to help prevent HIV from anal sex. The study will include approximately 210 HIV-negative cisgender men, transgender men and transgender women who have sex with men at sites in Malawi, Peru, South Africa, Thailand and the United States. Results of the study, anticipated in 2020, will impact the development of intervention strategies for future rectal microbicide drug trials.
What Do People Who Practice Anal Sex Desire for Preventing HIV?
10-April-2019
See Also